1. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.

    Annals of Oncology 27(4):668 (2016) PMID 26712905

    Fluorouracil-based adjuvant chemotherapy in gastric cancer has been reported to be effective by several meta-analyses. Perioperative chemotherapy in locally advanced resectable gastric cancer (RGC) has been reported improving survival by two large randomized trials and recent meta-analyses but t...
  2. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.

    Annals of Oncology 27(2):249 (2016) PMID 26598540

    Although tumor-infiltrating lymphocytes (TILs) have been associated with a favorable prognosis in triple-negative breast cancer (TNBC) patients, this marker is not currently considered robust enough for entering the clinical practice. In the present study, we assessed the clinical validity of th...
  3. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

    Annals of Oncology 26(12):2442 (2015) PMID 26387144 PMCID PMC4658543

    We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial. The intention-to-treat BIG 1-98 monotherapy cohort (5 years of therapy wit...
  4. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

    Annals of Oncology 26(8):1533 (2015) PMID 25939896 PMCID PMC4511219

    The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitti...
  5. De-escalation attempts for adjuvant trastuzumab: longer beats shorter.

    Annals of Oncology 26(7):1275 (2015) PMID 26002609

  6. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

    Annals of Oncology 26(4):682 (2015) PMID 25600567

    To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS). We identified patients with HER2-positive DCIS among a population of 1667 cases, prospectively diagnosed and surgically treated at the European Instit...
  7. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.

    Annals of Oncology 26(2):307 (2015) PMID 25411418

    Limited data are available on the prognostic value of changes in the biological features of residual tumours following neoadjuvant therapies in breast cancer patients. We collected information through the institutional clinical database on all consecutive breast cancer patients treated with neoa...
  8. The AURORA initiative for metastatic breast cancer.

    British Journal of Cancer 111(10):1881 (2014) PMID 25225904 PMCID PMC4229627

    Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecu...
  9. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

    Annals of Oncology 25(10):1871 (2014) PMID 25234545 PMCID PMC4176456

  10. Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature.

    European Journal of Cancer 50(6):1045 (2014) PMID 24529927

    Clinical decision-making in patients with early stage breast cancer requires adequate risk estimation by medical oncologists. This survey evaluates the agreement among oncologists on risk estimations and adjuvant systemic treatment (AST) decisions and the impact of adding the 70-gene signature t...
  11. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.

    Psycho-Oncology 23(3):322 (2014) PMID 24123459

    In a previous study, we found that patients who were offered the possibility of participation in a clinical trial had unexpressed concerns and fears that prevented them from making free or fully knowledgeable choices about their trial participation. In a selected population of patients who were ...
  12. Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer.

    Annals of Oncology 25(3):755 (2014) PMID 24458471 PMCID PMC4433528

  13. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.

    Breast Cancer Research and Treatment 143(1):159 (2014) PMID 24305979 PMCID PMC3913479

    There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of...
  14. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.

    European Journal of Cancer 49(15):3083 (2013) PMID 23777741

    Axillary dissection is increasingly forgone in early breast cancer patients with a clinically negative axilla. The GRISO 053 randomised trial recruited 435 patients of age over 45 years, tumour ≤1.4 cm and clinically negative axilla, to assess the importance of axillary radiotherapy versus no ax...
  15. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

    Annals of Oncology 24(9):2206 (2013) PMID 23917950 PMCID PMC3755334

    The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refi...
  16. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

    Annals of Oncology 24(7):1859 (2013) PMID 23532115

    Postsurgical treatment of ductal intraepithelial neoplasia (DIN) with standard doses of tamoxifen has not reached a consensus yet. Given positive results of low-dose tamoxifen on breast cancer biomarkers modulation, we analyzed a large cohort of DIN patients treated with low-dose tamoxifen or no...
  17. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

    Annals of Oncology 24(3):661 (2013) PMID 23022996

    The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis. We explored patterns of recurrence in 4837 women with breast cancer de...
  18. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.

    European Journal of Surgical Oncology (EJSO) 39(3):260 (2013) PMID 23313014

    A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features. We studied 1742 consecutive BC patients with I...
  19. Tumour dormancy and clinical implications in breast cancer.

    ecancermedicalscience 7:320 (2013) PMID 23717341 PMCID PMC3660156

    The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence...
  20. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

    Annals of Oncology 23(11):2843 (2012) PMID 22707751 PMCID PMC3477879

    To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosi...